Please Wait
Applying Filters...
menu
    • menu
    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Kewpie is your partner for Sodium Hyaluronate & Hyaluronic Acid// CEP, USDMF, KDMF & JDMF registered.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-24

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-03-17

    Virtual Booth

    Contact Supplier

    Menu

    Voxelotor

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 14,860Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Pfizer pulls sickle cell disease drug Oxbryta from global markets
    Pfizer pulls sickle cell disease drug Oxbryta from global markets

    26 Sep 2024

    // PRESS RELEASE

    https://investors.pfizer.com/Investors/News/news-details/2024/Pfizer-Voluntarily-Withdraws-All-Lots-of-Sickle-Cell-Disease-Treatment-OXBRYTA-voxelotor-From-Worldwide-Markets/default.aspx

    PRESS RELEASE
    26 Sep 2024
    Share Share
    NHS to provide Pfizer’s Voxelotor to treat sickle cell disease
    NHS to provide Pfizer’s Voxelotor to treat sickle cell disease

    03 May 2024

    // PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/nhs-pfizer-voxelotor-sickle-cell-disease/

    PHARMACEUTICAL TECHNOLOGY
    03 May 2024
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Voxelotor Tablets
    FDA Confirms Paragraph IV Patent Litigation for Voxelotor Tablets

    26 Jan 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-voxelotor-tablets-12918.pdf

    FDA
    26 Jan 2024
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Voxelotor Tablets for Oral Suspension
    FDA Confirms Paragraph IV Patent Litigation for Voxelotor Tablets for Oral Suspension

    26 Jan 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-voxelotor-tablets-for-oral-suspension-71916.pdf

    FDA
    26 Jan 2024
    Share Share
    Global Blood Therapeutics' Oxbryta (voxelotor) Receives Approval in Europe
    Global Blood Therapeutics' Oxbryta (voxelotor) Receives Approval in Europe

    13 Jun 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/oxbryta-epar-medicine-overview_en.pdf

    EMA
    13 Jun 2023
    Share Share
    Pfizer's Oxbryta (Voxelotor) Approved In Europe
    Pfizer's Oxbryta (Voxelotor) Approved In Europe

    06 Jun 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/oxbryta-epar-medicine-overview_en.pdf

    EMA
    06 Jun 2023
    Share Share